| 货号 | HF879026 |
|---|
| 品牌 | abinScience |
|---|
| 种属反应性 | Human |
|---|
| 应用 | ELISA, Bioactivity: FCM, Functional assay, Research in vivo |
|---|
| 宿主 | Human |
|---|
| 克隆类型 | Monoclonal |
|---|
| 同种型 | IgG1, kappa |
|---|
| 生物活性 | Treatment of HUVECs with Adalimumab for up to 12 hours shows no adverse effect on their cell viability, even with a 10-fold higher concentration of Adalimumab than used in this study [2]. The elimination half-life (t 1/2) of Adalimumab is long (~20 days) [1]. The enriched fluorescent-labelled adalimumab is observed mainly in major Oil red O-positive lesions documenting good tissue penetration of the drug into the atherosclerotic plaque, without background fluorescence of the vessel wall after vehicle control injection into hypercholesterolemic Ldlr -/- mice [2]. |
|---|
| 经测试应用 | FCM |
|---|
| 靶标 | C-domain 1, C-domain 2, Cachectin, ICD1, ICD2, Intracellular domain 1, Intracellular domain 2, N-terminal fragment, NTF, TNF, TNF-a, TNF-alpha, TNFA, TNFSF2, Tumor necrosis factor, Tumor necrosis factor ligand superfamily member 2, Tumor necrosis factor, membrane form, Tumor necrosis factor, soluble form |
|---|
| 内毒素水平 | < 10 EU/mg |
|---|
| 纯度 | >95% as determined by SDS-PAGE. |
|---|
| 纯化方式 | Protein A/G purified from cell culture supernatant. |
|---|
| Accession号 | P01375 |
|---|
| 状态 | Liquid |
|---|
| 保存溶液 |
0.01M PBS pH 7.4. Please refer to the specific buffer information in the hardcopy of datasheet or the lot-specific COA.
|
| 稳定性和存储 | Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt. |
|---|
| 别名 | ABP501, D2E7, Adalimumab, AdalimumabBeta, 331731-18-1 |
|---|
| 背景 | Tumor necrosis factor (TNFa/TNF-alpha) is a ~25 kDa protein. Cytokine that binds to TNFRSF1A/TNFR1 and TNFRSF1B/TNFBR. It is mainly secreted by macrophages and can induce cell death of certain tumor cell lines. It is potent pyrogen causing fever by direct action or by stimulation of interleukin-1 secretion and is implicated in the induction of cachexia, Under certain conditions it can stimulate cell proliferation and induce cell differentiation. Impairs regulatory T-cells (Treg) function in individuals with rheumatoid arthritis via FOXP3 dephosphorylation. Up-regulates the expression of protein phosphatase 1 (PP1), which dephosphorylates the key 'Ser-418' residue of FOXP3, thereby inactivating FOXP3 and rendering Treg cells functionally defective. TNFa is the therapeutic target of adalimumab (Humira). 2. Friedmann, E. et al. (2006) Nature cell biology 8, 843-8. PMID: 168299523. Jinesh G, G. et al. (2012) Journal of leukocyte biology 92, 233-44. PMID: 225179184. Nakahara, H. et al. (2003) Arthritis and rheumatism 48, 1521-9. PMID: 12794819 |
|---|
| 文献 | 1. Ternant D, et al. Pharmacokinetics and concentration-effect relationship of adalimumab in rheumatoid arthritis. Br J Clin Pharmacol. 2015 Feb;79(2):286-97. [HF879026]
2. Oberoi R, et al. Targeting Tumor Necrosis Factor-α with Adalimumab: Effects on Endothelial Activation and Monocyte Adhesion. PLoS One. 2016 Jul 28;11(7):e0160145. [HF879026] |
|---|
| Note | For research use only. Not suitable for clinical or therapeutic use. |
|---|
| Isotype Control | Human IgG1 Recombinant Isotype Control Antibody (13R4) (HV080507) |
|---|
